<p>The following adverse reactions are based on experience from clinical trials and on post marketing experience of Streptokinase.&nbsp;<br />
<br />
General disorders:</p>

<ul>
	<li><strong>Common</strong>: Headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise.</li>
</ul>

<p>Haemorrhage and bleeding:</p>

<ul>
	<li><strong>Common</strong>: Haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. Gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis.&nbsp;</li>
	<li><strong>Uncommon</strong>: Intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. Blood transfusions are rarely required.</li>
</ul>

<p>Immune system disorders:</p>

<ul>
	<li><strong>Very common</strong>: Development of antistreptokinase antibodies&nbsp;</li>
	<li><strong>Common</strong>: Allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension.</li>
</ul>

<p>Nervous system disorders:</p>

<ul>
	<li><strong>Rare</strong>: Neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain.</li>
</ul>

<p>Cardiac complication and vascular disorders:</p>

<ul>
	<li><strong>Very common</strong>: Hypotension, heart rate and rhythm disorders, angina pectoris.&nbsp;</li>
	<li><strong>Common</strong>: Recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema.&nbsp;</li>
	<li><strong>Uncommon</strong>: Cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism.</li>
</ul>

<p>Respiratory disorders:</p>

<ul>
	<li><strong>Very rare</strong>: Non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction.</li>
</ul>

<p>Gastrointestinal disorders:</p>

<ul>
	<li><strong>Common</strong>: Nausea, diarrhoea, epigastric pain and vomiting.</li>
</ul>